Journal: British Journal of Cancer
Article Title: Episodic Src activation in uveal melanoma revealed by kinase activity profiling
doi: 10.1038/sj.bjc.6605172
Figure Lengend Snippet: UM1 (06-12) and Mel270 treatment with Src inhibitors (PP1/PP2) identified eight substrates with a significant reduction in phosphorylation ( A ). The inhibition of EFS peptide phosphorylation by genetic (Src siRNA) and pharmacological means (PP1) in cell line Mel270, and PP1 treatment of cell lysates of UM (UM1) and metastasis tissue (MET3) ( B ).
Article Snippet: Blocking experiments were carried out with Src family-selective tyrosine kinase inhibitors, PP1, PP2 (Biomol International, LP, of Plymouth Meeting, PA, USA) and PP3 (the inactive analogue, Calbiochem), at an end concentration of 10 μ M in line with a large body of literature.
Techniques: Phospho-proteomics, Inhibition